Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
基本信息
- 批准号:8146139
- 负责人:
- 金额:$ 28.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-26 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirus VectorAdenovirusesAffectAgarAnimal ModelApoptosisBasic ScienceBindingBiologicalBiological AssayBreastBromodeoxyuridineCancer BiologyCancer EtiologyCancer cell lineCarboplatinCell CycleCell DeathCell NucleusCell ProliferationCellsCessation of lifeCisplatinClinicClinical TreatmentClinical TrialsCombined Modality TherapyComplexCytoplasmDevelopmentDiagnosticERBB2 geneEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErlotinibFluorescence-Activated Cell SortingFoundationsGenesGenetic TranscriptionGoalsGrantIn VitroInduction of ApoptosisInjection of therapeutic agentLeadLiposomesMalignant NeoplasmsMalignant neoplasm of ovaryMeasuresMediatingModelingMolecularMolecular TargetMusOutcomeOvarianPaclitaxelPathway interactionsPatientsPharmaceutical PreparationsPhasePhase I Clinical TrialsPhosphoproteinsPhosphorylationPhosphorylation SitePhosphotransferasesPlatinum CompoundsRegulationResearchResistanceRoleSerineSignal PathwaySignal TransductionSmall Interfering RNATaxane CompoundTherapeuticTransfectionTranslatingTumor Necrosis Factor-alphaTumorigenicityUnited StatesVariantWomanWorkXenograft Modelbasecancer cellcancer therapycell growthchemotherapyclinical Diagnosisdesigndocetaxelgene delivery systemgene therapyimprovedin vivoinnovationknock-downmalignant breast neoplasmmutantnew therapeutic targetnoveloverexpressionphase 1 studypre-clinicalpreventtaxanetherapeutic genetherapeutic targettooltreatment responsetumor
项目摘要
DESCRIPTION (provided by applicant): Our long-term goal is to develop novel targeted therapy strategies to treat advanced ovarian cancer. In our previous studies of E1A gene therapy for ovarian and breast cancer, we identified PEA15 as being responsible for the antiproliferative effects of E1A on cancer cells. Our subsequent explorations of the molecular mechanism of this phenomenon led us to the central hypothesis of this proposal: that PEA15 has a critical role in ovarian cancer tumorigenicity and treatment response. Supporting evidence for this hypothesis is as follows. First, PEA15 is known to sequester ERK in the cytoplasm, and ERK is known to be involved in cell cycling and enhanced survival of cancer cells. Second, cells in which PEA15 is not phosphorylated at serine 116 undergo apoptosis via tumor-necrosis factor (TNF) signaling, a major apoptosis pathway. Third, overexpression of PEA15 suppresses viability of ovarian cancer cells. Fourth, patients with ovarian cancers that overexpress PEA15 survive longer than those with low-PEA15-expressing tumors. Collectively, these findings implicate PEA15 as a key molecule in ovarian cancer via its ability to block ERK and enhance TNF signaling, and thus could be exploited as a dual-pathway therapeutic gene for patients with ovarian cancer. Our first major goal in this proposal is to delineate the mechanistic and functional significance of PEA15 in ovarian cancer cells. The second major goal is to develop PEA15 as a targeted molecule. To address these two goals, we have developed a comprehensive plan comprising three specific aims: (1) Determine the role of PEA15 in ovarian cancer tumorigenicity; (2) Determine the effects of PEA15 on the sensitivity of ovarian cancer cell to chemotherapy; and (3) Establish how PEA15 modulates erlotinib sensitivity in ovarian cancer cells. This proposal is innovative because PEA15 is thought to target both ERK and TNF signaling pathways, which have been implicated in cancer aggressiveness, induction of apoptosis, and regulation of sensitivity to chemotherapy and EGFR-tyrosine kinase inhibitors. The proposed research is highly relevant to improving outcomes for patients with ovarian cancer because understanding the biology of cancer will lead to the discovery of novel targets to be used in clinical diagnosis and treatment. The ultimate purpose of this project is to build a foundation upon which to design a clinical trial, based on basic research, of PEA15 as a novel target. The proposed research is highly relevant to improving outcomes for patients with ovarian cancer because understanding the biology of cancer will lead to the discovery of novel targets (PEA15 or molecules related to PEA-15) to be used in clinical diagnosis and treatment.
描述(由申请者提供):我们的长期目标是开发新的靶向治疗策略来治疗晚期卵巢癌。在我们之前对卵巢癌和乳腺癌的E1a基因治疗的研究中,我们发现PEA15与E1a对癌细胞的抗增殖作用有关。我们随后对这一现象的分子机制的探索使我们得出了这一提议的中心假设:PEA15在卵巢癌的致瘤性和治疗反应中起着关键作用。支持这一假设的证据如下。首先,已知PEA15将ERK隔离在细胞质中,ERK已知参与细胞周期和提高癌细胞的存活率。其次,PEA15在丝氨酸116处未被磷酸化的细胞通过肿瘤坏死因子(TNF)信号途径进行凋亡,这是一种主要的凋亡途径。第三,PEA15的过表达抑制了卵巢癌细胞的活力。第四,过度表达PEA15的卵巢癌患者比低表达PEA15的肿瘤患者存活时间更长。总之,这些发现表明PEA15是卵巢癌中的关键分子,它通过阻断ERK和增强肿瘤坏死因子信号转导而成为卵巢癌的关键分子,因此可以作为卵巢癌患者的双途径治疗基因。我们在这项提案中的第一个主要目标是描述PEA15在卵巢癌细胞中的机制和功能意义。第二个主要目标是将PEA15开发为靶向分子。为了解决这两个目标,我们制定了一个包括三个具体目标的综合计划:(1)确定PEA15在卵巢癌致瘤性中的作用;(2)确定PEA15对卵巢癌细胞对化疗的敏感性的影响;以及(3)确定PEA15如何调节卵巢癌细胞对厄洛替尼的敏感性。这一建议是创新的,因为PEA15被认为针对ERK和TNF信号通路,这两个信号通路与癌症侵袭性、诱导细胞凋亡以及调节对化疗和EGFR酪氨酸激酶抑制剂的敏感性有关。这项拟议的研究与改善卵巢癌患者的预后高度相关,因为了解癌症的生物学将导致发现新的靶点,用于临床诊断和治疗。这个项目的最终目的是建立一个基础,在此基础上设计一项以基础研究为基础的PEA15临床试验作为一个新的目标。这项拟议的研究与改善卵巢癌患者的预后高度相关,因为了解癌症的生物学将导致发现新的靶点(PEA15或与PEA-15相关的分子),用于临床诊断和治疗。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
- DOI:10.1158/1535-7163.mct-15-0243
- 发表时间:2015-12
- 期刊:
- 影响因子:5.7
- 作者:Bartholomeusz C;Xie X;Pitner MK;Kondo K;Dadbin A;Lee J;Saso H;Smith PD;Dalby KN;Ueno NT
- 通讯作者:Ueno NT
PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.
- DOI:10.1158/0008-5472.can-08-2592
- 发表时间:2008-11-15
- 期刊:
- 影响因子:11.2
- 作者:Bartholomeusz C;Rosen D;Wei C;Kazansky A;Yamasaki F;Takahashi T;Itamochi H;Kondo S;Liu J;Ueno NT
- 通讯作者:Ueno NT
PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin.
PEA-15在丝氨酸104和丝氨酸116上均未磷酸化可通过阻断β-catenin抑制卵巢癌细胞的肿瘤性和进展。
- DOI:10.1038/oncsis.2012.22
- 发表时间:2012-07-16
- 期刊:
- 影响因子:6.2
- 作者:Lee, J.;Bartholomeusz, C.;Krishnamurthy, S.;Liu, P.;Saso, H.;LaFortune, T. A.;Hortobagyi, G. N.;Ueno, N. T.
- 通讯作者:Ueno, N. T.
Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.
- DOI:10.1016/j.canlet.2014.09.033
- 发表时间:2015-01-28
- 期刊:
- 影响因子:9.7
- 作者:Xie X;Tang H;Pengliu;Kong Y;Wu M;Xiao X;Yang L;Gao J;Wei W;Lee J;Bartholomeusz C;Ueno NT;Xie X
- 通讯作者:Xie X
Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.
双磷酸化 PEA-15 通过削弱 SCLIP 的微管不稳定作用,使卵巢癌细胞对紫杉醇敏感。
- DOI:10.1158/1535-7163.mct-12-0737
- 发表时间:2013
- 期刊:
- 影响因子:5.7
- 作者:Xie,Xuemei;Bartholomeusz,Chandra;Ahmed,AhmedA;Kazansky,Anna;Diao,Lixia;Baggerly,KeithA;Hortobagyi,GabrielN;Ueno,NaotoT
- 通讯作者:Ueno,NaotoT
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Naoto T Ueno其他文献
Navigating the androgen receptor landscape in triple-negative breast cancer
在三阴性乳腺癌中探索雄激素受体领域
- DOI:
10.1016/s1470-2045(25)00029-4 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:35.900
- 作者:
Nithya Sridhar;Naoto T Ueno - 通讯作者:
Naoto T Ueno
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
III 期炎性乳腺癌 1 线与 2-3 线新辅助治疗后的临床结果。
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:3.8
- 作者:
F. Nakhlis;Samuel M. Niman;Naoto T Ueno;Elizabeth Troll;Sean J. Ryan;E. Yeh;Laura Warren;J. Bellon;Beth Harrison;T. Iwase;H. T. Carisa Le;S. Saleem;M. Teshome;Gary J. Whitman;Wendy A Woodward;Beth Overmoyer;S. Tolaney;M. Regan;F. Lynce;R. Layman - 通讯作者:
R. Layman
Naoto T Ueno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Naoto T Ueno', 18)}}的其他基金
Developing a novel combination immunotherapy for triple-negative breast cancer
开发针对三阴性乳腺癌的新型联合免疫疗法
- 批准号:
10734197 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10836263 - 财政年份:2022
- 资助金额:
$ 28.38万 - 项目类别:
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10390676 - 财政年份:2022
- 资助金额:
$ 28.38万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
8265321 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7630446 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7500877 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7252750 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7462422 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7894611 - 财政年份:2007
- 资助金额:
$ 28.38万 - 项目类别:
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 28.38万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 28.38万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Young Scientists (B)